profit from every SEK 100 of sales.
SEK 0SEK 100
Elekta
SEK 59.45-2.14% today
+7.1% in 1 year
1-year low SEK 45.701-year high SEK 63.25
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Elekta sold, what it kept, and what it did with the cash.
Sales went from SEK 16.9 billion in 2023 to SEK 16.7 billion in 2026, with -SEK 519 million of profit last year.
SalesProfit
Elekta handed back 66% of the cash it generated last year.
SEK 917M
Free cash flow 2026SEK 1.4B
Bought back its own shares–
Paid as dividendsSEK 917M
Cash vs. debtSEK 3.2B vs. SEK 7.3B
Elekta vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| Elekta | No profit yet | ||
 Abbott Laboratories | 29.3× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 38.2× · Expensive | ||
 Edwards Lifesciences | 56.1× · Expensive |
AI analysis
An AI analyst reads Elekta's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 16,869 | 18,119 | 18,016 | 16,718 | |
| 6,349 | 6,777 | 6,746 | 6,249 | |
| 1,865 | 2,260 | 900 | 101 | |
| 2,570 | 3,163 | 2,200 | 1,350 | |
| 943 | 1,302 | 237 | -519 | |
| 2.47 | 3.41 | 0.62 | -1.36 | |
| 37.6% | 37.4% | 37.4% | 37.4% | |
| 11.1% | 12.5% | 5.0% | 0.6% | |
| 5.6% | 7.2% | 1.3% | -3.1% |
Balance sheet
| In millions of SEK | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 29,608 | 31,413 | 28,977 | 26,955 |
| Cash | 3,270 | 2,771 | 2,947 | 3,189 |
| Total debt | 6,668 | 7,248 | 7,567 | 7,331 |
| Total liabilities | 19,875 | 20,633 | 20,130 | 19,807 |
| 9,729 | 10,775 | 8,802 | 7,099 | |
| 382 | 382 | 382 | 382 | |
| 7.3% | 8.9% | 4.4% | 0.6% | |
| 9.7% | 12.1% | 2.7% | -7.3% |
Cash flow
| In millions of SEK | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,964 | 2,461 | 2,626 | 2,464 | |
| 1,564 | 1,644 | 1,570 | 1,072 | |
| 400 | 817 | 1,056 | 1,392 | |
| Dividends paid | 917 | 917 | 917 | 917 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 2.8×
- 1.4×
- 16.3×
- 19.9×
- 6.1%
- -2.3%
- 4.0%
Profitability
- 37.4%
- 0.6%
- -3.1%
- –
- 0.6%
- 5.3%
- –
- –
- –
- –
Growth
- −0.3%
- –
- –
- –
- −0.0%
Financial health
- 3.1×
- 1.03
- –
- –
- 0.87
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 38%of 948
Bottom 30%of 871
Bottom 15%of 868
Top 15%of 985
4.0%of the share price, paid each year
On $1,000 invested$40a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
: 65.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
19No pass
Philip Fisher
25No pass
Peter Lynch
21No pass
Joel Greenblatt
0No pass
Charlie Munger
14No pass
Terry Smith
9No pass
Questions about Elekta
Is Elekta a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Elekta AI analysis
What does Elekta do?
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It is in Medical Devices, based in Stockholm, Sweden, with 4,353 employees.
Does Elekta pay a dividend?
Yes. At today's price the dividend is 4.0% a year. In 2026 it paid out SEK 917 million in dividends.
Is Elekta stock halal?
Questionable. Elekta sits in a grey zone: its debt is 32% of its market value, between 30% and 33%. How we check
How has Elekta stock done over the past year?
Up 7.1% over the past twelve months, to SEK 59.45. It traded between SEK 45.70 and SEK 63.25 and is 6.0% below its high.
Who are Elekta's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Elekta's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.